股东警告：Ademi LLP调查SOC Telemed，Inc.在与患者广场的交易中是否获得了公平的价格。

MILWAUKEE, Feb. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating SOC Telemed (NASDAQ: TLMD) for possible breaches of fiduciary duty and other violations of law in its transaction with Patient Square.

Click here to learn how to join the action: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Ademi LLP alleges SOC Telemed's financial outlook and prospects are excellent and yet SOC Telemed shareholders will receive only $3 per share. The merger agreement unreasonably limits competing bids for SOC Telemed by prohibiting solicitation of further bids, and imposing a significant penalty if SOC Telemed accepts a superior bid. SOC Telemed insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of SOC Telemed's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for SOC Telemed.

If you own SOC Telemed common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP